Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

ABSTRACT: Metronomic chemotherapy, the delivery of doses in a low, regular manner so as to avoid toxic side effects, was introduced over 12 years ago in the face of substantial clinical and preclinical evidence supporting its tumor-suppressive capability. It constituted a marked departure from the classic maximum-tolerated dose (MTD) strategy, which, given its goal of rapid eradication, uses dosing sufficiently intense to require rest periods between cycles to limit toxicity. Even so, upfront tumor eradication is frequently not achieved with MTD, whereupon a de facto goal of longer-term tumor control is often pursued. As metronomic dosing has shown tumor control capability, even for cancers that have become resistant to the same drug delivered under MTD, the question arises whether it may be a prefe

SUBMITTER: Hahnfeldt P 

PROVIDER: S-EPMC3696500 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature